company background image
NNG

NanoGroup WSE:NNG Stock Report

Last Price

zł1.21

Market Cap

zł20.3m

7D

-10.2%

1Y

-77.0%

Updated

29 Sep, 2022

Data

Company Financials
NNG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

NNG Stock Overview

NanoGroup S.A. operates as a biotechnology company.

NanoGroup Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NanoGroup
Historical stock prices
Current Share Pricezł1.21
52 Week Highzł5.40
52 Week Lowzł1.07
Beta1.54
1 Month Change-23.80%
3 Month Change5.22%
1 Year Change-76.95%
3 Year Change-27.11%
5 Year Changen/a
Change since IPO-73.11%

Recent News & Updates

Shareholder Returns

NNGPL Life SciencesPL Market
7D-10.2%-3.5%-4.3%
1Y-77.0%-38.7%-33.1%

Return vs Industry: NNG underperformed the Polish Life Sciences industry which returned -38.7% over the past year.

Return vs Market: NNG underperformed the Polish Market which returned -33.1% over the past year.

Price Volatility

Is NNG's price volatile compared to industry and market?
NNG volatility
NNG Average Weekly Movement18.6%
Life Sciences Industry Average Movement7.0%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: NNG is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: NNG's weekly volatility has increased from 13% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aPiotr Pietrzakhttps://nanogroup.eu

NanoGroup S.A. operates as a biotechnology company. It develops and licenses early-stage biotechnology and medical projects in the areas of oncology, transplantology, and blood donations to international biotech companies and pharmaceutical companies. NanoGroup S.A was incorporated in 2016 and is based in Warsaw, Poland.

NanoGroup Fundamentals Summary

How do NanoGroup's earnings and revenue compare to its market cap?
NNG fundamental statistics
Market Capzł20.26m
Earnings (TTM)-zł9.99m
Revenue (TTM)zł470.75k

43.1x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NNG income statement (TTM)
Revenuezł470.75k
Cost of Revenuezł135.71k
Gross Profitzł335.04k
Other Expenseszł10.32m
Earnings-zł9.99m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 25, 2022

Earnings per share (EPS)-0.60
Gross Margin71.17%
Net Profit Margin-2,121.99%
Debt/Equity Ratio0%

How did NNG perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NNG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NNG?

Other financial metrics that can be useful for relative valuation.

NNG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue40.5x
Enterprise Value/EBITDA-6.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NNG's PS Ratio compare to its peers?

NNG PS Ratio vs Peers
The above table shows the PS ratio for NNG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.4x
IGN Inno-Gene
1.2xn/azł38.6m
RVU Ryvu Therapeutics
16x-6.8%zł601.1m
RDG Read-Gene
4xn/azł28.1m
BGD Biogened
0.5xn/azł34.6m
NNG NanoGroup
43.1xn/azł20.3m

Price-To-Sales vs Peers: NNG is expensive based on its Price-To-Sales Ratio (43.1x) compared to the peer average (5.4x).


Price to Earnings Ratio vs Industry

How does NNG's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Sales vs Industry: NNG is expensive based on its Price-To-Sales Ratio (43.1x) compared to the European Life Sciences industry average (4.6x)


Price to Sales Ratio vs Fair Ratio

What is NNG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NNG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio43.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NNG's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NNG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NNG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NNG's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is NanoGroup forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoGroup has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of NNG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • NanoGroup competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has NanoGroup performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-41.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NNG is currently unprofitable.

Growing Profit Margin: NNG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NNG is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare NNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NNG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.3%).


Return on Equity

High ROE: NNG has a negative Return on Equity (-186.37%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is NanoGroup's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NNG's short term assets (PLN2.4M) do not cover its short term liabilities (PLN4.4M).

Long Term Liabilities: NNG's short term assets (PLN2.4M) do not cover its long term liabilities (PLN7.6M).


Debt to Equity History and Analysis

Debt Level: NNG is debt free.

Reducing Debt: NNG had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NNG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NNG has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.1% each year.


Discover healthy companies

Dividend

What is NanoGroup current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

NanoGroup Dividend Yield vs Market
How does NanoGroup dividend yield compare to the market?
SegmentDividend Yield
Company (NanoGroup)n/a
Market Bottom 25% (PL)3.1%
Market Top 25% (PL)9.3%
Industry Average (Life Sciences)0.7%
Analyst forecast in 3 Years (NanoGroup)n/a

Notable Dividend: Unable to evaluate NNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NNG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NNG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NNG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Piotr Pietrzak

0.67yr

Tenure

Mr. Piotr Mierzejewski serves as Management Board Member at StartVenture@Poland. Mr. Mierzejewski serves as President of Management Board at NanoGroup S.A. since 2022. He served as Chairman of Supervisory...


Leadership Team

Experienced Management: NNG's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: NNG's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of NNG?
Owner TypeNumber of SharesOwnership Percentage
Private Companies550,1003.3%
Individual Insiders4,180,00025.0%
Institutions4,701,56828.1%
General Public7,316,21543.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 6 shareholders own 56.32% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
27.29%
Copernicus Capital Towarzystwo Funduszy Inwestycyjnych S.A.
4,570,000PLN5.5m0%12.63%
24.96%
Tomasz Ciach
4,180,000PLN5.1m0%no data
3.28%
Startventure@Poland Sp. z o.o. S.K.A.
550,100PLN665.6k-46.59%no data
0.69%
BNPP Asset Management Holding
115,423PLN139.7k-25.54%no data
0.089%
Towarzystwo Funduszy Inwestycyjnych BGZ BNP Paribas S.A.
14,870PLN18.0k-63.1%0.01%
0.0076%
AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.
1,275PLN1.5k0%no data

Company Information

NanoGroup S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: NanoGroup S.A.
  • Ticker: NNG
  • Exchange: WSE
  • Founded: 2016
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł20.265m
  • Shares outstanding: 16.75m
  • Website: https://nanogroup.eu

Location

  • NanoGroup S.A.
  • Rakowiecka 36
  • Warsaw
  • 02-532
  • Poland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NNGWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNDec 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.